KVG quality: organise the evidence before the form arrives

Quality exists in a medical practice before legislation gives it a name. It appears in a handover, case review, discussed incident, amended procedure or completed training. Yet when evidence is requested, those activities are often scattered: minutes held by a medical assistant, a certificate in an email, or a measure known to only one partner. The KVG reform that took effect in 2021 introduced a national framework intended to make this improvement explicit. The mistake would be to sell every practice a standardised compliance programme now. The outpatient agreement was submitted to the Federal Council on 11 September 2025, but the FMH states that it is not in force. This insight separates what is settled from what remains in preparation and identifies a reasonable first purchase: an evidence inventory that does not anticipate unpublished requirements. It places that offer in an ethical B2B acquisition strategy separate from promises of new patients. General analysis updated on 7 August 2026. It does not replace clinical guidance, a Federal Council decision or support from the competent professional bodies.

Article 58a KVG required federations of healthcare providers and insurers to conclude national quality-development agreements. These agreements must govern measures, verification, reporting and the consequences of non-compliance. Service providers must follow the applicable agreement once it has been approved and entered into force.

The revised framework took effect on 1 April 2021. The Federal Council sets four-year objectives, while the Federal Quality Commission supports and advises the parties. This structure does not replace clinical work. It is intended to make quality development within compulsory health insurance more coordinated, measurable and continuous.

How to read the diagram. The law creates the mechanism; the sector agreement defines how it applies. Until approval, useful preparation means taking inventory, not claiming certification.

Text alternative. The law leads to a sector agreement. Before approval, a practice can map current work; approval is followed by introduction and then the applicable measures.

For a practice, the first question is not “Which form must we complete?” but “Which agreement covers our activity, and what is its current status?” Hospitals already have an agreement approved in 2024. The outpatient medical-practice sector follows a different timetable. Combining those scopes would impose the wrong evidence on the wrong teams.

The quality agreement for medical practices is not yet in force, according to FMH information consulted in August 2026. The FMH and prio.swiss submitted it to the Federal Council on 11 September 2025. The full content and public catalogue of measures are expected after approval, so practices should not buy supposedly definitive compliance now.

This distinction determines whether an offer is credible. An agency or consultant cannot turn submission into a detailed operating obligation. It can explain the legal framework, monitor the agreement's status and prepare documentary foundations likely to remain useful: named owners, activities already performed, evidence locations and review dates.

The FMH announced that approval would be followed by an introductory phase of at least two years. That phase is intended, among other things, to prepare and test implementation and address how the additional work is financed. The timetable makes a preparation service plausible but rules out artificial urgency. A practice buys clarity, not a shortcut to future compliance.

The most prudent first purchase is a readiness inventory covering existing quality work, owners, available evidence, incidents and reviews, tools, sensitive data and documentation gaps. It certifies nothing. It gives the practice a map of its current operation and a list of reversible actions to take before final requirements are published.

The inventory starts with a few real workflows: handling a critical result, maintaining continuity during an absence, handing over between professionals, managing a high-risk medicine or addressing a complaint. For each, the team describes what happens, who decides and where a trace remains. The partner does not judge medical practice; it makes the system visible and identifies where specialist expertise is required.

The deliverable may include a “practice — owner — evidence — frequency — risk” matrix, a list of missing records and monitoring of the agreement. The partner agrees the fee, duration and number of workflows in advance. This gives a practice a bounded first step that can be completed within an agreed period rather than an open-ended programme.

A folder is not enough because it may describe a process without proving that people understand, use and review it. Useful evidence links a practice to an owner, a frequency, a trace and a decision. It shows what changed after review without exposing health data unnecessarily.

Quality becomes fragmented when every item of evidence depends on one person. A procedure in a shared folder, training in HR software and lessons learned in a messaging tool do not automatically tell one coherent story. The inventory creates a common index and defines access rights. It does not centralise clinical data when that is unnecessary.

Data protection is a design constraint. The provider should request the minimum, use anonymised examples wherever possible and set rules for deleting copies. Any acquisition campaign that asks for patient files at first contact should be rejected. The opening conversation concerns the organisation, never an identifiable clinical situation.

The Federal Statistical Office counted 13,931 medical practices and outpatient centres with their own infrastructure at the end of 2021. This is an indication of the professional landscape, not an immediately available market. Practices differ by discipline, size, organisation, applicable agreement and ability to finance preparation.

The audience must therefore be segmented before activation. Group practices, recently acquired businesses, multi-site centres and teams changing systems tend to have more documentation dependencies. A well-organised solo practice may have no need. Size is not a verdict; it supports only a hypothesis about complexity.

Market size must never justify anxious mass solicitation. It helps structure research: choose a discipline, interview a small number of practices, test whether the language is understood and confirm that an inventory can actually be bought. The offer remains at partner-research stage until price, capacity and payment terms are documented.

A measure becomes useful evidence when it addresses a defined problem, has an owner, creates a proportionate trace and leads to review. The number of actions is not a measure of quality. One well-documented cycle—observe, decide, act and verify—is worth more than a catalogue of procedures with no demonstrable use.

The practice can select one bounded workflow and describe its initial state. It then names the action, owner and expected signal. At review, the team records what it learned and decides whether to maintain, change or stop the measure. This supports the quality culture announced by the parties to the agreement without pretending to know the future catalogue.

The consultant supplies a documentation method. Medical societies, tariff partners and authorities retain their roles. A question involving a clinical choice, interpretation of a requirement or financing goes to the competent owner. This allocation protects the team from the false simplicity of a universal template.

The Healthcare and practices market page connects this insight with changes in tariffs, organisation and data protection while keeping their decisions distinct.

Acquisition should begin with an observable organisational need: a partnership, new site, new system, growing team or preparation for a published agreement. The message offers one question and a limited diagnostic. It alleges neither non-compliance nor clinical risk nor an immediate obligation. Channels are chosen to match trust and the partner's delivery capacity.

How to read the diagram. The regulatory timetable determines the commercial pace. If the offer is unclear or the agreement insufficiently precise, waiting may be the right decision.

Text alternative. Research and interviews precede activation. Only a paid inventory validates the first purchase; without a transaction, the campaign stops or changes direction.

Professional networks, associations, software providers and organisational specialists can act as referrers. Content answers questions about status and method. Email and calls are reserved for accounts whose change is public or voluntarily disclosed. Broad advertising is tested only when the message remains informative and delivery capacity is confirmed.

Continuity may involve periodic review of evidence, support when a team or system changes, and adaptation once the agreement and its measures apply. Every intervention must have a separate trigger and fee. An empty subscription with no review or decision is not quality improvement.

The practice may retain the inventory and update it internally. If it commissions follow-up, the partner checks only the agreed items: deadlines, owners, documents and review cycles. Clinical data remains under the practice's responsibility and is never used in commercial communication.

Commercial measurement covers new practices that paid for an inventory and those that commission a justified second stage. Requests for information and webinar registrations are not revenue. Keeping them separate makes the cost of acquisition visible without overstating the value of a professional audience.

Which prerequisites protect both the practice and the partner?

The partner needs demonstrable expertise, confidentiality safeguards, suitable insurance, a data-minimisation protocol and an escalation procedure. It also confirms its price, timing, capacity and limits. The practice appoints an owner, grants access only to necessary information and approves each report.

Before a campaign, getfishnet asks for a redacted sample deliverable, contractual scope and rejection criteria. Statements about the agreement are dated and tied to their status. Any regulatory development triggers editorial review before the message is reused. Information that is accurate in August 2026 may become outdated after a Federal Council decision.

The opportunity therefore remains conditional. It may create prompt revenue for a partner selling a sound inventory to new practices. It does not yet establish the accepted price, margin, monthly volume or continuation rate. Interviews and transactions must confirm those figures before results are presented.

The complimentary eligibility assessment reviews your offer, the practices you can genuinely serve, the agreement's status, the initial purchase and the ethical boundaries. It establishes whether getfishnet could build a tailored strategy around your acquisition challenge and whether there is a useful basis for development, with no commitment.

The authoritative references used are the Federal Office of Public Health, Federal Statistical Office, Federal Quality Commission, FMH and prio.swiss. They establish the framework, market volume and status of the agreement. They prove neither a detailed obligation that has not yet been published nor nationwide commercial demand.